- Text
Drugmaker pays $442m in Plavix patent case
(Getty Images)
NEW YORK - A major generic drugmaker has paid Bristol-Myers Squibb Co. (BMY) and Sanofi SA more than $442 million to end a decade-long patent infringement case over blockbuster blood thinner Plavix, the world's second-best-selling drug.
Apotex Corp., Canada's biggest drugmaker, has paid the two brand-name drugmakers $442.2 million in damages for selling a generic version of Plavix in 2006.
Apotex launched its copycat version while it was still in a court dispute with Bristol and Sanofi, partners who jointly market Plavix. Apotex argued at the time that key patents on Plavix were invalid, doing what's called an "at-risk launch" of its generic version of Plavix.
A federal judge later ruled the Plavix patent was valid, leading to the damages payment.
- 10 Best Countries To Live and Work Abroad
- 4 Things Not to Buy at Costco
- Top 10 Cities for Single Men
- Analysts: Europe bank run is under way
- Top 10 Places to Live in 2011
- Chilean copper giant Codelco CEO resigns
- Used Cars: 5 to Avoid (and 5 Better Alternatives)
- How to handle sexual misconduct at work
- Injury forces Michael McKean out of Broadway show
- Reverse Cell Phone Lookup Service is Free and Simple
- Doctors report rise in kids eating detergent packs
- Why that flat Facebook IPO isn't so bad after all
- 5 Things You Should Buy at Costco
- Made in USA: 5 Great American Cars Made Here
- The holy grail of leadership
- Can Tim Cook do what Steve Jobs couldn't?
